10% of MS cases are due to anti-Neurofascin autoantibody
Posted: Sun Apr 14, 2019 10:40 am
Anti-Neurofascin-155 is an auto-antibody whose presence has been separated from standard MS, like it was for anti-AQP4 and anti-MOG before.
This report points to that around 10% of MS cases are in fact due to anti-Neurofascin.
The involvement of anti-neurofascin 155 antibodies in central and peripheral demyelinating diseases
https://nnjournal.net/article/view/3032
[...] In addition to the peculiarities of peripheral demyelination associated with presence of NF155 antibodies, diseases of the central nervous system also show particular features when anti-NF155 antibodies are identified. Ten percent of patients fulfilling the diagnostic criteria for MS, may have antibodies against NF155[...]
[...]Anti-NF155 antibodies may form a biomarker for a particular form of demyelinating neurological disease. NF155 does not activate a complement. Therefore, at least in theory, patients with anti-NF155 antibodies might respond well to therapies using ocrelizumab and rituximab. “Anti-NF155 demyelination” may be a different disease with peculiar presentation and therapeutic management.
This report points to that around 10% of MS cases are in fact due to anti-Neurofascin.
The involvement of anti-neurofascin 155 antibodies in central and peripheral demyelinating diseases
https://nnjournal.net/article/view/3032
[...] In addition to the peculiarities of peripheral demyelination associated with presence of NF155 antibodies, diseases of the central nervous system also show particular features when anti-NF155 antibodies are identified. Ten percent of patients fulfilling the diagnostic criteria for MS, may have antibodies against NF155[...]
[...]Anti-NF155 antibodies may form a biomarker for a particular form of demyelinating neurological disease. NF155 does not activate a complement. Therefore, at least in theory, patients with anti-NF155 antibodies might respond well to therapies using ocrelizumab and rituximab. “Anti-NF155 demyelination” may be a different disease with peculiar presentation and therapeutic management.